Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.72 +1.13%

+$0.32 today

Market cap
$144.76M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.24M

Average 0.28M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$177.23M

FY 2025 · Annual

Investing Cash Flow

$45.01M

FY 2025 · Annual

-79.4% YoY

Financing Cash Flow

$44,000.00

FY 2025 · Annual

-100.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Depreciation & Amortization4.84M5.69M6.82M7.22M7.32M
Deferred Income Tax7.24M0000
Stock-Based Compensation23.24M26.3M24.91M24.69M14.01M
Change in Working Capital(17.62M)104.41M(34.38M)8.9M(50.4M)
Accounts Receivables(6.9M)5.34M(28.96M)27.46M4.64M
Inventory(4.55M)0000
Accounts Payables6.43M(1.23M)4.81M706K(2.47M)
Other Working Capital(12.61M)100.29M(10.23M)(19.27M)(52.57M)
Other Non-Cash Items6.16M(13.65M)(2.17M)(4.88M)42.92M
Operating Cash Flow(81.68M)3.55M(111.62M)(191.54M)(177.23M)
Capital Expenditures(15.32M)(7.86M)(4.32M)(3.1M)(1.7M)
Acquisitions (Net)028.74M000
Purchases of Investments(248.73M)(216.67M)(460.3M)(461.52M)(264.95M)
Sales of Investments166.73M189.5M460.69M683.13M311.66M
Other Investing Activities9K(28.73M)000
Investing Cash Flow(97.32M)(35.02M)(3.92M)218.51M45.01M
Debt Repayment0(9.38M)(12.5M)(4.08M)0
Common Stock Issued056.27M11.97M96.53M376K
Common Stock Repurchased(7K)0000
Dividends Paid00000
Other Financing Activities4.25M1.42M138.08M1.61M(332K)
Financing Cash Flow3.26M48.31M137.55M94.05M44K
Effect of Forex Changes00000
Net Change in Cash(175.74M)16.84M22.01M121.02M(132.17M)
Free Cash Flow(97M)(4.31M)(115.93M)(194.64M)(178.93M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$191.1M
+ D&A$7.3M
+ Stock-Based Comp$14.0M
+ Deferred Tax$0
- Working Capital-$50.4M
+ Other Non-Cash$42.9M
= Operating Cash Flow-$177.2M
- Capex-$1.7M
= Free Cash Flow-$178.9M

Analysis

FY2025 free cash flow is -$178.9M. FCF conversion is 93.6% of net income. Operating cash flow was -$177.2M, with capex of -$1.7M. The largest bridge item is Working Capital at -$50.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingNov 9, 2026
4Statement of changes in beneficial ownershipSep 22, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

Does STRO generate free cash flow?

Sutro Biopharma, Inc. (STRO) generated -$178.93M of free cash flow in fiscal 2025.

How much operating cash flow does STRO produce?

Operating cash flow was -$177.23M, before capital expenditures of $1.70M.